Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-04-18
2006-04-18
Nguyen, Dave (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S024000, C424S093100, C424S093200, C536S023100, C536S024100, C435S006120
Reexamination Certificate
active
07030099
ABSTRACT:
A DNA comprising a 609 bp base sequence from −559 to +50 when the first base sequence of exon 1 of the midkine gene, a human retinoic acid-responsive growth/differentiation factor was set as +1, or a DNA comprising a 251 bp base sequence from −213 to +38 when the transcription initiation point of the c-erbB-2 gene belonging to the EGF receptor family and having a tyrosine kinase activity was set as +1 has a tumor-specific transcription activity, and the promoter activity thereof is high, and therefore is very important as a tumor-specific promoter for use in the suicide gene therapy that combines the use of a gene for a drug metabolizing enzyme and a prodrug for cancer therapy, the gene therapy of cancer using an expression vector that contains a gene encoding a cytokine, and the gene therapy of cancer using an oncolytic virus.
REFERENCES:
patent: 5728379 (1998-03-01), Martuza et al.
patent: 6607879 (2003-08-01), Cocks et al.
patent: WO 00/15209 (2000-03-01), None
patent: WO 00/15242 (2000-03-01), None
Tweddle, et al. (2001) Am. J. Pathol., 158(6): 2067-76.
Stryer (1988) Biochemistry, 3rd Ed., Freeman and Co., New York, NY., pp. 718, 803-805.
Levedeva, et al. (2001) Annu. Rev. Pharmacol. Toxicol., 41: 403-19.
Deonarain (1998) Exp. Opin. Ther. Pat., 8(1): 53-69.
Gorecki (2001) Exp. Opin. Emerging Drugs, 6(2): 187-98.
Verma, et al. (1997) Nature, 389: 239-42.
Eck, et al. (1996) Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., McGraw-HIll, New York, NY., pp. 77-101.
Ausubel, et al. (1995) Short Protocols In Molecular Biology, 3rd Ed., Wiley & Sons, Inc., New York, NY, pp. 3-1 to 3-29.
Sequence Search Results, Result No. 1, Document labelled “Search 1” (us-10-333-013-copy-539-609.rni).
Tagawa, et al. (1999) “Preferential expression of a suicide gene in tumor cells is achieved with a promoter of the midkine gene whose expression is up-regulated in a varitey of human tumors”, Cancer Gene Therapy, 6(6 Suppl.): S21-S-22, Abstract No. PD-81.
Adachi, Yasuo, et al., “Midkine Promotor-Based Adenoviral Vector Gene Delivery for Pediatric Solid Tumor”, Cancer Research, vol. 60, No. 16, Aug. 15, 2000, pp. 4305-4310.
Ishii, S. et al., “Charaterization of the Promotor Region of the Human C-ERBB-2 Protooncogene”, Proceedings of the National Academy of Sciences of the USA, New York, NY, U.S., vol. 84, No. 13, Jul., 1987, pp. 4374-4378.
Hollywood, D.P., et al., “A Novel Transcription Factor, OB2-1, is Required for Overexpression of the Proto-Oncogene C-ERBB-2 in Mammary Tumour Lines”, Embo Journal, Oxford University Press, Surrey, G.B., vol. 12, No. 6, 1993, pp. 2369-2375.
Pandha Hardev, S., et al., “Generic Prodrug Activation Therapy for Breast Cancer: A Phase I Clinical Trial of erbβ-2-directed Suicide Gene Expression”, Journal of Clinical Oncology, vol. 17, No. 7, Jul., 1999, pp. 2180-2189.
Grooteclaes, Madeline, et al., “The 6-Kilobase c-erbβ2 Promotor Contains Positive and Negative Regulatory Elements Functional in Human Mammary Cell Lines”, Cancer Research, vol. 54, No. 15, 1994, pp. 4193-4199.
M. Miyauchi, et al., “Frequent Expression of Midkine Gene in Esophageal Cancer Sugggests a Potential Usage of Its Promoter for Suicide Gene Therapy”, Jpn. Journal of Cancer Research, 1999, vol. 90, No. 4, pp. 469 to 475.
R.C. Pedraza, et al., “A Retinoic Acid-Responsive Element in Human Midkine Gene”, J. Biochem., 1995, vol. 117, No. 4, pp. 845 to 849.
K. Uehara, et al., “Genomic Stucture of Human Midkine (MK), a Retinoic Acid-Responsive Growth/Differentiation Factor”., J. Biochem., (1992), vol. 111, No. 5, pp. 563 to 567.
G.K. Scott, et al., “Binding of an ETS-related Protein within the Dnase I Hypersensitive Site of the HER2
eu Promoter in Human Breast Cancer Cells”, J. Biol. Chem., 1994, vol. 269, No. 315,pp. 19848 to 19858.
F.L. Moolten., et al., “Drug sensitivity (“suicide”) genes for selective ancer chemotherapy”, Cancer Gene Ther., (1994). vol. 1, No. 4, pp. 279 to 287.
C. Heise, et al., “Replication-selective adenoviruses as oncolytic agents”, J. Clin. Invest., Apr., 2000, vol. 105, No. 7, pp. 847 to 851.
Kelly Robert M.
Nguyen Dave
Research Corporation Technologies Inc.
Scully , Scott, Murphy & Presser, P.C.
LandOfFree
Tumor specific promoters of the midkine gene that allow for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor specific promoters of the midkine gene that allow for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor specific promoters of the midkine gene that allow for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3557561